Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324027 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL31090251 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL888101 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12469395 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12469742 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL197305 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12469885 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL9361385 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12469729 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL4431897 | 0.97 | TSHR (0.53) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050226844-A1 | Valency platform molecules comprising carbamate linkages | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050220785-A1 | Methods and formulations for reducing circulating antibodies | ENGLE STEVEN B | 2005-10-06 | — | — | US | disclosed |
| US-20030018190-A1 | Valency platform molecules comprising carbamate linkages | JONES DAVID S (US) | 2003-01-23 | — | — | US | disclosed |
| US-20020160964-A1 | Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same | JACK RICHARD M (US) | 2002-10-31 | — | — | US | disclosed |
| US-20020155107-A1 | Methods and formulations for reducing circulating antibodies | ENGLE STEVEN B (US) | 2002-10-24 | — | — | US | disclosed |
| US-6458953-B1 | VALENCY PLATFORM MOLECULES WHICH ACT AS SCAFFOLDS TO WHICH ONE OR MORE MOLECULES MAY BE COVALENTLY TETHERED TO FORM A CONJUGATE. MORE PARTICULARLY, THE PRESENT INVENTION PERTAINS TO VALENCY PLATFORM MOLECULES WHICH COMPRISE A CARBAMATE | LA JOLLA PHARMACEUTICAL COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-6399578-B1 | REACTION PRODUCT; REDUCING CONCENTRATION OF ANTIBODIES; ORGANS TRANSPLANT | LA JOLLA PHARMACEUTICAL COMPANY | 2002-06-04 | — | — | US | disclosed |
| EP-1137628-A1 | MOLECULAR SCAFFOLDS ACTING AS TEMPLATES COMPRISING CARBAMATE LINKAGES | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 2001-10-04 | — | — | EP | disclosed |
| EP-1137652-A2 | CONJUGATES COMPRISING GALACTOSE ALPHA 1,3 GALACTOSYL EPITOPES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1135167-A2 | METHODS AND FORMULATIONS FOR REDUCING CIRCULATING ANTIBODIES | LA JOLLA PHARMACEUTICAL (US) | 2001-09-26 | — | — | EP | disclosed |
| US-20010010818-A1 | Administering to the individual an effective amount of an epitope-presenting carrier | ENGLE STEVEN B (US) | 2001-08-02 | — | — | US | disclosed |
| WO-2000033887-A2 | METHODS AND FORMULATIONS FOR REDUCING CIRCULATING ANTIBODIES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034296-A2 | CONJUGATES COMPRISING GALACTOSE ALPHA 1,3 GALACTOSYL EPITOPES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034231-A1 | MOLECULAR SCAFFOLDS ACTING AS TEMPLATES COMPRISING CARBAMATE LINKAGES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050220785-A1 | Methods and formulations for reducing circulating antibodies | CD47, HLA-DRB1, FCGR3B | MEN1 642/4885KMT2A 2299/4885TSHR 3385/4885 |
| US-20010010818-A1 | Administering to the individual an effective amount of an epitope-presenting carrier | HLA-DRB1, CD47, FCGR2A | MEN1 414/4885KMT2A 2094/4885TSHR 3189/4885 |
| US-20020160964-A1 | Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same | B3GAT3, B4GALT1, FUT5 | MEN1 2678/4885KMT2A 1873/4885TSHR 3848/4885 |
| US-20050226844-A1 | Valency platform molecules comprising carbamate linkages | NEDD8, CYP2C8, VIM | MEN1 1766/4885KMT2A 1586/4885TSHR 3183/4885 |
| US-20020155107-A1 | Methods and formulations for reducing circulating antibodies | CD47, HLA-DRB1, FCGR3B | MEN1 642/4885KMT2A 2299/4885TSHR 3385/4885 |
| US-20030018190-A1 | Valency platform molecules comprising carbamate linkages | NEDD8, CA13, VIM | MEN1 1980/4885KMT2A 1801/4885TSHR 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.